33
/pt/
AIzaSyB4mHJ5NPEv-XzF7P6NDYXjlkCWaeKw5bc
November 1, 2025
2135693
178559
2
Public Timelines
FAQ Receber premium

28 set 2017 ano - FDA sent letters to IR opioid analgesic manufacturers informing them that their products that are intended to be used in the outpatient setting will be subject to the same REMS requirements as the ER/LA opioid analgesics.

Adicionado na linha do tempo:

13 nov 2018
0
0
521

Data:

28 set 2017 ano
Agora
~ 8 years ago